Kornimate/medical-research-clean huggingface dataset:
l-dep as an initial treatment for ebv-hlh

Conditions: Hemophagocytic Lymphohistiocytosis

Summary: this study aimed to investigate the efficacy and safety of pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (l-dep) as an initial treatment for epstein barr virus-induced hemophagocytic lymphohistiocytosis.


Eligibility criteria:
inclusion criteria: 1. patients were older than 14 years of age 2. diagnosed as ebv-hemophagocytic lymphohistiocytosis (hlh) 3. patients did not receive any treatment for hlh before 4. informed consent exclusion criteria: 1. heart function above grade ii (nyha) 2. accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2 3. pregnancy or lactating women 4. allergic to pegaspargase, doxorubicin or etoposide 5. active bleeding of the internal organs 6. uncontrollable infection 7. history of acute and chronic pancreatitis 8. participate in other clinical research at the same time

Keywords: pegaspargase hemophagocytic lymphohistiocytosis epstein barr virus initial treatment
antimanic drug use in pregnancy

Conditions: Bipolar Disorder; Pregnancy

Summary: the purpose of this study is to learn about the effects of bipolar disorder or the use of antimanic medications on the mother's health and wellbeing during pregnancy and for the first postpartum year. infant health and development are also assessed during the first year. participation in the study includes 7 study visits, three in pregnancy and four postpartum.


Eligibility criteria:
inclusion criteria for bipolar subjects: * age 18 or older * pregnant at 20 weeks or more * women must receive ob care * english-speaking * dsm-iv diagnosis of bp, any subtype inclusion criteria for non-bipolar control subject: * age 18 or older * pregnant at 20 weeks or more * english-speaking * women must receive ob care. * women may have past or present subclinical major depressive disorder according to the dsm-iv. exclusion criteria for all: * women must have no active alcohol abuse or dependence, active abuse or dependence of opiates, inhalants, amphetamines including ecstasy or lsd, active iv drug abuse, or methadone maintenance. * women must not take drugs in the fda categories d or x. additional exclusion criteria for control subjects: * women must have no lifetime history of bipolar disorder or antimanic drug use.

Keywords: bipolar disorder pregnancy infant development
different acupoints compatibility difference of the effect of treatment of the primary insomnia

Conditions: Primary Insomnia

Summary: with primary insomnia as the research object, by the method of multi-center rct and needle single cavity and different acupoints compatibility treatment for primary insomnia, to pittsburgh sleep quality index(psqi) and evaluation, sleep log evaluation and polysomnogram(psg) as the means, such as the single cavity with different acupoints compatibility evaluate clinical curative effect of treating primary insomnia.

in order to establish a spectrum of acupoints compatibility of the law, is clear about the factors affecting the compatibility effect of acupoints, the formation of strong operability of acupoints compatibility optimization evaluation method, the project choice of the clinical acupuncture and moxibustion have curative effect of primary insomnia as the breakthrough point of the study, carried out clinical multi-center rct research, through objective and scientific evaluation method, comparing the effect of different acupoints compatibility. primary insomnia in clinical common disease, frequently-occurring disease, acupuncture curative effect is distinct, disease diagnosis, curative effect evaluation standard. previous clinical data also show that the primary insomnia is acupuncture clinical diseases. this project by primary insomnia as the research object, research to better guide clinical practice, improve the clinical curative effect, promote acupuncture of the inheritance and innovation, promote scientification of acupuncture and moxibustion, modernization and internationalization, and will have broad prospect of application and significant scientific research value.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of insomnia 's disease; * aged 18-60 (including 18 and 60); * does not attend other clinical researchers; * participation in the researchers signed informed consent and voluntary; * pittsburgh sleep index (psqi) index \> 7 points; * athens scale or 6 points; * depression scale and anxiety scale 50 points or less. exclusion criteria: * breathing-related sleep disorder; * circadian rhythm disorders; * sleep disorders; * drug-induced insomnia (such as drug abuse, drug treatment); * sleep disorders caused by poor diet, lifestyle factors(long-term excessive drinking, coffee, tea, etc.); * all systemic diseases (such as pain, fever, cough, surgery, etc.) and the external environment disturbance factors; * with cardiovascular, lung, liver, kidney and hematopoietic system such as serious primary diseases; * patients with mental illness; * pregnancy or breast-feeding women; * acupoints with severe skin infections; * patients who are afraid of acupuncture; * advanced malignant tumor or other serious wasting disease, infection and bleeding; * who do not meet the inclusion criteria, poor compliance, treatment, not according to stipulations can not judge the curative effect or data not congruent affect curative effect and safety of judgment; * caused by excessive anxiety and depression of patients with insomnia.

Keywords: different acupoints compatibility
modulaar - a module based and scalable system for silver-ager in austria

Conditions: Quality of Life

Summary: in this research project a module based ambient assisted living solution will be provided to elderly living in assisted living homes. those products and services seek to impact quality of life of the elderly and have positive effects on their environment.


Eligibility criteria:
inclusion criteria: * 60 years and older * informed consent * resident of an assisted living home of the samariterbund burgenland rettung und soziale dienste gmbh exclusion criteria: * relevant health threatening event or death * mini mental state score \<17

Keywords: technology acceptance ambient assisted living independent living quality of life socioeconomic impact usability of information and communication technologies
a study of linifanib (abt-869) in combination with carboplatin/paclitaxel in japanese subjects with non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: the primary objective of this study is to assess the safety and pharmacokinetics of linifanib, and identify tolerable dose of linifanib (abt-869) in combination with carboplatin and paclitaxel in japanese subjects with advanced or metastatic non-small cell lung cancer (nsclc). secondary objective is to obtain a preliminary efficacy of anti-tumor activity in the subjects as first-line treatment.


Eligibility criteria:
inclusion criteria * the subject must be 20 and older years of age. * the subject must have cytologically or histologically confirmed non-squamous nsclc. subjects may have a mixed histology but must be predominantly non-squamous to be eligible. * the subject must have advanced or metastatic (stage iv \[according to american joint committee on cancer (ajcc) staging manual, 7th edition\]) disease that is not amenable to surgical resection or radiation with curative intent. * the subject must have not received prior chemotherapy for nsclc. * the subject has measurable disease, defined as at least 1 unidimensionally measurable lesion on a ct scan as defined by response evaluation criteria in solid tumors (recist) version 1.1. * the subject has an easter cooperative oncology group (ecog) performance score of 0-1. * the subject must have adequate bone marrow, renal and hepatic function. exclusion criteria * the subject has hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (cremophor). * the subject has received any anti-cancer therapy for treatment of nsclc including investigational agents, immunotherapy, traditional chinese medicine/herbal remedies, hormonal, "targeted" agents (i.e., erlotinib, imatinib), biologic therapy or cytotoxic chemotherapy (i.e., alkylating agents, microtubule inhibitors, antimetabolites). * the subject has a history of another active cancer within the past 5 years except cervical cancer in situ, in situ carcinoma of the bladder, squamous cell or basal cell carcinoma of the skin. * the subject has active ulcerative colitis, crohn's disease, celiac disease or any other conditions that interfere with absorption. * the subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities. * the subject is pregnant or breast feeding. * the subject has nsclc with a predominant squamous cell histology.
preoperative bath in patients submitted to hip arthroplasty

Conditions: Surgical Wound Infection

Summary: clinical trial for prevention, randomized, controlled, blinded, parallel, with three arms which purpose is verify the effects of nursing intervention preoperative bathing with 4% chlorhexidine gluconate, 10% povidone iodine (pvpi) and soap without antiseptic, for the prevention of surgical site infection (ssi) in patients undergoing hip arthroplasty.

despite the recommendation in several guidelines of preoperative bathing with 4% chlorhexidine gluconate as a measure for the prevention of ssi, there is no evidence in the literature that support this practice. the objective of this study is to evaluate the effect of nursing intervention: preoperative bath using 4% chlorhexidine gluconate solutions, 10% povidone iodine degermante or soap without antiseptic for the prevention of ssi in patients undergoing elective hip arthroplasty surgery. the specific objectives are to compare the incidence of ssi in the three interventions, to assess the most effective intervention for the prevention of surgical infection and to estimate the frequency of allergic reactions caused by the use of the solutions. two intervention groups (4% chlorhexidine gluconate and pvpi10%) and a control group (without antiseptic soap) composed of 52 patients undergoing hip arthroplasty in each group will be randomized to perform the baths in the period from may 2015 to june 2017. before the intervention, nasal swabs will be collected of patients to investigate colonization by staphylococcus aureus. the expected result is lower isc rate with the proposed measures.

Eligibility criteria:
inclusion criteria: * be 18 or older; * elective procedure of total hip arthroplasty * no report of infectious focus at the surgical site * know to respond to the clinical signs of a surgical infection or having a person responsible with this ability * do not be a nasal carrier of staphylococcus aureus before surgery * have access to fixed or mobile phone exclusion criteria: * patient treating surgical site infection * emergency hip prosthesis surgery or orthopedic trauma * nasal carriers of staphylococcus aureus before surgery * previous history of allergic reactions to the products used in the bat

Keywords: preoperative care baths chlorhexidine soaps povidone-iodine arthroplasty, replacement, hip surgical wound infection
aspirin resistance in systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus

Summary: this study examine whether patients with lupus respond to aspirin , and if not, if that is related to inflammation. we examine the ability of aspirin to inhibit the production of thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane production is inhibited by meloxicam.

premature cardiovascular disease is a major cause of mortality in patients with systemic lupus erythematosus (sle) with the risk of myocardial infarction increased up to 50-fold. in addition to defining the mechanisms for accelerated atherosclerosis it is important to define the effects of drugs used to reduce cardiovascular risk in high-risk patients. low dose aspirin, by inhibiting thromboxane a2 biosynthesis, has profound antiplatelet effects, but some patients have impaired thromboxane suppression - a phenomenon termed aspirin resistance. an explanation is that aspirin-independent thromboxane synthesis may occur through enhanced cox-2 activity, as would occur in an inflammatory condition such as lupus. however, little is known about the effects of low-dose aspirin in sle. thus, we propose to test the following hypothesis: 1) that aspirin insensitive thromboxane biosynthesis is increased in patients with lupus and is mediated by increased cox-2 activity.

Eligibility criteria:
inclusion criteria: * written informed consent. * age \>18 yrs. * sle meeting acr criteria {tan, cohen, et al. 1982 1482 /id} for at least 6 months.(sle group) * stable disease activity as evidenced by no change in immunosuppressive therapy in the past 1 month. * if female of childbearing potential must use an effective method of birth control exclusion criteria. * renal disease (creatinine \>1.5 mg/dl, dialysis, 2+ or more proteinuria) * previous or current history of peptic ulcer disease or gastrointestinal bleed. * previous or current thromboembolic or ischemic cardiovascular event (stroke, myocardial infarction, angina) - can do aspirin part of study. * currently taking an anticoagulant or antiplatelet agent (besides aspirin). * thrombocytopenia (platelet count \<135,000) * pregnancy * allergy to aspirin, nsaids * nsaids in the previous week
effect of the abutment-prosthesis connection on marginal bone loss and gingival sealing around dental implants

Conditions: Jaw, Edentulous, Partially

Summary: in dental implant restoration, available literature demonstrates the advantage of using tall abutments, with a change of diameter with respect to the implant and a conical internal connection in the abutment-implant gap. however, for multiple restorations, the abutment-prosthesis connection has not been studied in detail. the "multi-unit" systems, both standard and brand specific, have either a flat or butt joint or an cone. in any case, both are external connection systems. recently, an internal-type abutment-prosthesis connection system has been developed. although it is proving its usefulness in single restorations, its use in multiple restorations compared to traditional systems has not been studied. therefore, taking into account all of the above, the present study has the overall objective of analyzing marginal bone loss (mbl) and adaptation of soft tissues by comparing a multiple prosthesis system of the "external, flat" type versus an external system of the "internal, conical" type.


Eligibility criteria:
inclusion criteria: * kennedy class i or ii (unilateral or bilateral free end) or iii (posterior intermediate edentulous section) mandibular requiring 2 implants to restore at least 2 molars, 2 molars and 1 premolar, or 2 premolars and 1 molar. * possibility of placing a transgingival abutment at least 2 mm high. exclusion criteria: * need for simultaneous bone augmentation. * heavy smokers (\>10 cigarettes/day). * uncontrolled type 1 or 2 diabetes (hga1c\>8). * known autoimmune or inflammatory disease. * serious blood disorders, such as hemophilia or leukemia. * local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology). * liver or kidney dysfunction/failure. * currently receiving cancer treatment or within 18 months from completion of radio- or chemotherapy. * long-term history of oral bisphosphonates use (i.e., 10 years or more). * history of intravenous bisphosphonates. * long-term (\>3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system 3 months before inclusion. * severe osseous diseases (e.g., paget disease of bone). * pregnant women or nursing mothers. * not able or not willing to follow instructions related to the study procedures.
efficacy study of a bioelectric dressing to treat skin graft donor site wounds

Conditions: Burns; Wound Healing

Summary: the purpose of this study is to determine whether the use of a bioelectric wound dressing is effective in the healing of skin graft donor site wounds.


Eligibility criteria:
inclusion criteria: * wounds resulting from skin graft * split thickness wound * wound size greater than 2x2 cm * wounds must be ≥5 cm away from all other wounds * participant agrees to participate in follow-up evaluation * participant must be able to read and understand informed consent, and sign the informed consent exclusion criteria: * concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study * participant is to receive another topical antimicrobial agent other than the study dressing * participant with sensitivity or adverse reactions to silver or zinc * pregnancy or nursing an infant or child * immunosuppression * active or systemic infection * peripheral vascular occlusive disease * collagen vascular disease * connective tissue disease * participant undergoing active cancer chemotherapy * chronic steroid use * decision impairment

Keywords: burns wounds and injuries skin grafts, bioelectric grafting, skin
effects of multimodal pain therapy in patients with mixed chronic pain syndromes

Conditions: Chronic Pain

Summary: complex and chronified pain syndromes requires a specialized therapeutic concept. from patients with chronic low back pain the investigators know, that an interdisciplinary multi-modal approach may improve the therapeutic success. in this observational study the investigators investigated if the multi-modal pain therapy is also effective in patients with mixed chronic pain syndromes.

the multi-modal pain therapy includes: * specific drug therapy * pain education * psychological therapy * physical therapy * behavioral therapy * work hardening * bio-feedback * ergotherapy

Eligibility criteria:
inclusion criteria: * age \>= 18 years and \<= 65 years * verified chronic pain for more than 6 month exclusion criteria: * application for a pension * non-accordance with multi-modal pain therapy * dominant geriatric symptoms * dominant psychiatric symptoms

Keywords: multi-modal pain therapy, chronic pain
safety study of natalizumab to treat multiple sclerosis (ms)

Conditions: Relapsing-Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis

Summary: the primary objective of this study is to compare the pharmacokinetic (pk) and pharmacodynamics (pd) of single subcutaneous (sc) and intramuscular (im) doses of 300 mg natalizumab to intravenous (iv) administration of 300 mg natalizumab in multiple sclerosis (ms) participants. the secondary objectives are to investigate the safety, tolerability and pk of repeated natalizumab doses administered sc and im, to investigate the immunogenicity of repeated natalizumab doses administered sc and im, to explore proof of concept within the secondary progressive multiple sclerosis (spms) population using change from baseline in clinical measures including: expanded disability status scale (edss), multiple sclerosis functional composite scale (msfc), symbol digit modalities test (sdmt), visual analogue scale (vas), and visual function test; and brain magnetic resonance imaging (mri) measures including: number of new or newly-enlarging t2 hyperintense lesions, number of new t1 hypointense lesions, number of new gadolinium-enhancing (gd+) lesions, whole brain atrophy, magnetization transfer ratio (mtr), and diffusion tensor imaging (dti) and to observe the effect of natalizumab administered iv and sc on brain mri measures in participants with relapsing forms of ms.


Eligibility criteria:
key inclusion criteria: * for arms 1,2,3 and 4: diagnosis of secondary progressive multiple sclerosis (spms) * for arms 5 and 6: diagnosis of relapsing forms of multiple sclerosis (ms). * no past history of receiving natalizumab. key exclusion criteria: * for arms 1,2,3 and 4 diagnosis of primary progressive ms or relapsing-remitting ms. * form arms 5 and 6: diagnosis of primary progressive ms or secondary progressive ms without the occurrence of relapses. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: natalizumab multiple sclerosis tysabri ®
nettle and cranberry capsules for prevention of urinary tract infection

Conditions: Urinary Tract Infection

Summary: this study investigates whether the oral intake of a nettle and cranberry complex capsule may prevent recurrent urinary tract infection (ruti). participants will be aged between 30 - 75 years of age, with confirmed diagnosis of uti status. the participants will be assessed for several parameters and asked to take 2 nettle and cranberry complex capsules twice daily for 8 weeks. the parameters will include international prostate symptoms score (ipss), overactive bladder symptom score (oabss), international consultation on incontinence questionnaire - overactive bladder (iciq-oab), 3-day bladder diary (3dbd), and urine routine.

urinary tract infections (utis) are one of the most common bacterial infections affecting women. uti occurs in 50-80% of women in the general population. about one in four women with one uti episode will go on to develop frequent recurrences. recurrent urinary tract infection (ruti) is defined as repeated uti with a frequency of at least two episodes in the preceding six months or three episodes in the past year. ruti has been regarded as a substantial global healthcare problem. this investigation is a randomized, double-blind study. subjects with confirmed diagnosis of ruti are randomly assigned to control group or treatment group, and asked to orally intake 2 capsules of either placebo or nettle and cranberry complex capsules twice daily. participants will be assessed for parameters, including international prostate symptoms score (ipss) (male only), overactive bladder symptom score (oabss), international consultation on incontinence questionnaire - overactive bladder (iciq-oab), 3-day bladder diary (3dbd) and urine routine. the assessments are conducted at baseline, 4 weeks, and 8 weeks after the oral intake period. the parameters are used to compare and evaluate whether the nettle and cranberry complex capsule can prevention ruti.

Eligibility criteria:
inclusion criteria: * aged between 30 and 75 years * at least two episodes in 6 months, or at least three episodes of a uti in 12 months. exclusion criteria: * pregnancy women * diabetes * history of anatomical urogenital anomalies, urogenital tract surgery * history of acute or chronic renal failure, nephrolithiasis * history of intestinal diseases causing malabsorption * anticoagulant medication in the last month * immunocompromise * known allergy or intolerance to cranberry

Keywords: nettle cranberry prevention urinary tract infection recurrent infection inflammation
predictive factors of morbidity and mortality and overall survival of patients with gastric cancer : a case series

Conditions: Gastric Cancer; Mortality of Gastric Cancer; Overall Survival of Patients With Gastric Cancer

Summary: this is a retrospective study extending over a period of three years concerning patients with gastric adenocarcinoma hospitalized in the digestive cancer surgery and liver transplant service of the ibn rochd university hospital center in casablanca. evaluation from a series of 80 cases of gastric adenocarcinomas, follow-up to determine the prognostic factors influencing mortality, morbidity and survival.


Eligibility criteria:
inclusion criteria: * patients with gastric cancer exclusion criteria: * patients with benign tumors or other pathologies requiring gastric resection

Keywords: gastric cancer mortality, gastric cancer treatment